Hydrapharm : Anatablok Nootropic

Anatablok is the exciting new nootropic from Hydrapharm that contains the popular ingredient anatabine. This powerful ingredient is focused towards improving cognitive functions such as memory, concentration and attention, as well as providing anti-inflammatory properties to complement its psychological benefits. The inclusion of vitamin D and vitamin A complements anatabine perfectly with the emerging evidence for these vitamins suggesting they play a key role in the development and functioning of the brain.

Users of this supplement can expect to experience enhanced cognitive abilities such as greater memory capacity, increased spatial memory, being sharper and more attuned to your environment due to enhanced concentration and attention skills and significant reductions in aches and pains from its anti-inflammatory properties - both from the gym and in everyday life.

IMPORTANT: USERS OF ANATABLOK SHOULD NOTE THAT IT CONTAINS 2MG OF PURE ANATABINE PER CAPSULE. THIS IS EQUIVALENT TO 4.4MG OF ANATABINE CITRATE.

What is Anatabine?

Anatabine is one of the pharmacologically active alkaloids present in tobacco and is commonly found in plants of the Solanaceae family. It is chemically similar to nicotine in regards to its structure. It is found in foods such as red peppers, potatoes and tomatoes, but in low concentrations.

Anatabine works through its ability to inhibit monoamine oxidase, an activity that is beneficial for treating various psychological disorders. The dysfunction of monoamine oxidase, too little or too much of this activity, is thought to play a role in a number of psychiatric and neurological disorders.

Research on Nootropic Effects

Research on anatabine have found it to be beneficial for improving memory, spatial memory and attention (1,2). One study found it to significantly reduce the memory impairment caused by dizocilpine, which binds to and inhibits the serotonin and dopamine transporters, and work as an antagonist to it (1). This same study found anatabine to also attenuate the attentional impairment effects of dizocilpine in a signal detection attentional task. The authors of this study concluded that follow up studies on anatabine are needed to determine their efficacy as therapeutics for memory and attentional dysfunctions.

Another study found anatabine to be effective in providing improvements in spatial memory – both as an early and late introduction of treatment for brain trauma (2). The conclusions drawn from this study found it to efficacious in improving long-term behaviour and pathology outcomes.

Powerful Role in Reducing Inflammation

Anatabine has demonstrated anti-inflammatory effects in in-vivo and in-vitro studies and shown to reduce musculoskeletal aches and pains (3,4,5,6,7). It works through reducing amyloidosis and neuro-inflammation.

One study found 82% of 282 participants to state anatabine was beneficial for one or more joint pain conditions in the knee, wrists/hands/fingers, shoulder, and back, most often due to osteoarthritis or injury to the joint (3). The researchers found anatabine to reduce joint pain and stiffness, with most respondents reporting anatabine to eliminate joint pain altogether and an excellent choice for improving joint pain, stiffness, functionality and overall effects. These studies provide conclusive evidence for the role of anatabine in reducing inflammation and subsequently pain and stiffness around varying joints.

Emerging Evidence of the Role of Vitamin D and the Brain

Vitamin D is well known to act as a neuro-steroid that modulates many brain functions. Growing evidence indicates that vitamin D plays a crucial role in brain development, neurotransmission, neuroprotection and immunomodulation – although the exact mechanism it works through is poorly understood at this moment in time. Emerging evidence has found vitamin D to play a beneficial role in treating psychological conditions (8,9,10), but further studies are needed in to order determine the exact mechanism it exerts its influence through and to determine which specific conditions it can provide therapeutic effects for.

1. Edward D Levin, Ian Hao, Dennis A Burke, Marty Cauley, Brandon J Hall, Amir H Rezvani. Effects of tobacco smoke constituents, anabasine and anatabine, on memory and attention in female rats. Journal of Psychopharmacology Vol 28, Issue 10, pp. 915 – 922.

2. Ferguson S, Mouzon B, Paris D, Aponte D, Abdullah L, Stewart W, Mullan M, Crawford F. Acute or Delayed Treatment with Anatabine Improves Spatial Memory and Reduces Pathological Sequelae at Late Time-Points after Repetitive Mild Traumatic Brain Injury. J Neurotrauma. 2017 Apr 15;34(8):1676-1691.

3.Megha Verma, David Beaulieu-Abdelahad, Ghania Ait-Ghezala, Rena Li, Fiona Crawford, Michael Mullan, and Daniel Paris Chronic Anatabine Treatment Reduces Alzheimer’s Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD. PLoS One. 2015; 10(5): e0128224.

4. Paris D, Beaulieu-Abdelahad D, Bachmeier C, et al. Anatabine lowers Alzheimer’s Abeta production in vitro and in vivo. Eur J Pharmacol. 2011;670(2–3):384–91. [PubMed].

5. Paris D, Beaulieu-Abdelahad D, Mullan M, et al. Amelioration of experimental autoimmune encephalomyelitis by anatabine. PLoS One. 2013;8(1):e55392. [PMC free article] [PubMed].

6. Paris D, Beaulieu-Abdelahad D, Abdullah L, et al. Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation. Eur J Pharmacol. 2013;698(1–3):145–53. [PubMed].

7. Caturegli P, De Remigis A, Ferlito M, et al. Anatabine ameliorates experimental autoimmune thyroiditis. Endocrinology. 2012;153(9):4580–7. [PubMed].

8. Rejnmark L, Bislev LS, Cashman KD, et al. Non-skeletal health effects of vitamin D supplementation: A systematic review on findings from meta-analyses summarizing trial data. Slominski AT, ed. PLoS ONE. 2017;12(7):e0180512. doi:10.1371/journal.pone.0180512.

9.Föcker, M., Antel, J., Ring, S. et al. Eur Child Adolesc Psychiatry (2017) 26: 1043. https://doi.org/10.1007/s00787-017-0949-3.

10. XiaoyingCuia, HelenGoochaAlicePettyaJohn J.McGrathabcDarrylEyles. Vitamin D and the brain: Genomic and non-genomic actions. Molecular and Cellular Endocrinology Volume 453, 15 September 2017, Pages 131-143.